These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8816151)

  • 1. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma.
    Campbell WN; Hendrix E; Cryz S; Cross AS
    Clin Infect Dis; 1996 Jul; 23(1):179-81. PubMed ID: 8816151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
    Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
    Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.
    Cryz SJ; Fürer E; Germanier R
    J Infect Dis; 1985 Apr; 151(4):665-71. PubMed ID: 3882856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group.
    Donta ST; Peduzzi P; Cross AS; Sadoff J; Haakenson C; Cryz SJ; Kauffman C; Bradley S; Gafford G; Elliston D; Beam TR; John JF; Ribner B; Cantey R; Welsh CH; Ellison RT; Young EJ; Hamill RJ; Leaf H; Schein RM; Mulligan M; Johnson C; Abrutyn E; Griffiss JM; Slagle D
    J Infect Dis; 1996 Sep; 174(3):537-43. PubMed ID: 8769611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Sadoff JC; Fürer E
    Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans.
    Cryz SJ; Mortimer P; Cross AS; Fürer E; Germanier R
    Vaccine; 1986 Mar; 4(1):15-20. PubMed ID: 3962447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine.
    Cryz SJ; Cross AS; Sadoff GC; Que JU
    Eur J Immunol; 1988 Dec; 18(12):2073-5. PubMed ID: 3220104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
    Welch PG; Fattom A; Moore J; Schneerson R; Shiloach J; Bryla DA; Li X; Robbins JB
    J Am Soc Nephrol; 1996 Feb; 7(2):247-53. PubMed ID: 8785394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta.
    Breukels MA; Rijkers GT; Voorhorst-Ogink MM; Zegers BJ; Sanders LA
    J Infect Dis; 1999 May; 179(5):1152-6. PubMed ID: 10191217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections.
    Clements A; Jenney AW; Farn JL; Brown LE; Deliyannis G; Hartland EL; Pearse MJ; Maloney MB; Wesselingh SL; Wijburg OL; Strugnell RA
    Vaccine; 2008 Oct; 26(44):5649-53. PubMed ID: 18725260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children.
    Ahmed A; Li J; Shiloach Y; Robbins JB; Szu SC
    J Infect Dis; 2006 Feb; 193(4):515-21. PubMed ID: 16425130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
    Cryz SJ; Fürer E; Sadoff JC; Germanier R
    Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
    [No Abstract]   [Full Text] [Related]  

  • 15. Protection against fatal Klebsiella pneumoniae sepsis in the squirrel monkey Saimiri sciureus after immunization with a capsular polysaccharide vaccine.
    Postal JM; Gysin J; Crenn Y
    Ann Inst Pasteur Immunol; 1988; 139(4):401-7. PubMed ID: 3048318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Hegerle N; Choi M; Sinclair J; Amin MN; Ollivault-Shiflett M; Curtis B; Laufer RS; Shridhar S; Brammer J; Toapanta FR; Holder IA; Pasetti MF; Lees A; Tennant SM; Cross AS; Simon R
    PLoS One; 2018; 13(9):e0203143. PubMed ID: 30188914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against Klebsiella pneumoniae in the murine infection model.
    Hussein KE; Bahey-El-Din M; Sheweita SA
    Microb Pathog; 2018 Jun; 119():12-18. PubMed ID: 29626658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
    Cryz SJ; Sadoff JC; Cross AS; Fürer E
    Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
    Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
    Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.